LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

BACKGROUND: Severe COVID-19 pneumonia results from a hyperinflammatory immune response (cytokine storm, CS), characterized by GM-CSF mediated activation and trafficking of myeloid cells, leading to elevation of downstream inflammatory chemokines (MCP-1, IL-8, IP-10), cytokines (IL-6, IL-1), and othe...

Descripción completa

Detalles Bibliográficos
Autores principales: Temesgen, Zelalem, Burger, Charles D., Baker, Jason, Polk, Christopher, Libertin, Claudia, Kelley, Colleen, Marconi, Vincent C., Orenstein, Robert, Durrant, Cameron, Chappell, Dale, Ahmed, Omar, Chappell, Gabrielle, Badley, Andrew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109186/
https://www.ncbi.nlm.nih.gov/pubmed/33972949
http://dx.doi.org/10.1101/2021.05.01.21256470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109186/
https://www.ncbi.nlm.nih.gov/pubmed/33972949
http://dx.doi.org/10.1101/2021.05.01.21256470

Ejemplares similares